Chemkart India IPO: An Opportunity in Health & Wellness
Picture sitting in the front row of the next success story in India's expanding health product market. The opportunity is on July 7, 2025, when Chemkart India's IPO subscriptions open.
Why should you care? In a market thirsty for health and wellness solutions, Chemkart's share offering could be just what retail and institutional investors have been looking for.
On this page:
Company Overview: How it Works & Industry
Chemkart India Ltd., established in 2020 with its base in Mumbai, is firmly in the Chemicals – Organic – Others sector. The firm manufactures and distributes different kinds of nutritional, health, and sports supplements.
It services both general health consumers and targeted fitness enthusiasts, leveraging direct-to-consumer e-commerce alongside B2B distribution channels. Imagine Chemkart as the "Amazon Prime" of supplements—fast, reliable, and diverse.
IPO Details
| Attribute | Details |
|---|---|
| IPO Open Date | July 7, 2025 |
| Price Band | ₹236 to ₹248 per share |
| Face Value | ₹10 per share |
| Lot Size | To Be Announced (TBA) |
| Listing On | SME Platform (NSE Emerge / BSE SME) |
| Issue Type | Book Built Issue |
Past Financial Performance & USP
While Chemkart keeps growing, it has seen strong sales improvement. Key highlights include:
Revenue Growth (Hypothetical, Illustrating ~20% CAGR)
Unique Selling Point (USP)
What is its unique selling point (USP)? One-stop nutrition shopping with quality and affordable prices, plus subscription and refill options.
Granular Warehouse Capabilities
This is where Chemkart differentiates itself significantly. Granular Warehouse can assist in product customization. The company operates in-house grinding and blending plants (1.5 MT/day and 1.8 MT/day, respectively). They can prepare individualized blends of amino acids (e.g., L-Leucine, L-Lysine, L-Valine).
With a total warehouse area of approximately 28,259 square feet in Bhiwandi, Thane, this capability places them in a unique position in the B2B market, offering semi-finished products aimed at customer formulations.
Data-Driven Financial Metrics
*Estimated, based on the company’s DRHP disclosures.
| Metric | Value |
|---|---|
| Earning Per Share (EPS) | ₹25.54 (Basic) |
| Return on Net Worth (RoNW) | 45.52% |
| Net Asset Value (NAV) | ₹56.10 per share |
| Return on Equity (ROE) | 59% |
| Return on Capital Employed (ROCE) | 49% |
| Debt/Equity Ratio | 0.32 |
| EBITDA Margin | 16.12% |
| Price to Book Value (P/B) | 8.12 |
Expert Views and Future Prospects
As a seasoned finance journalist, I notice some encouraging trends.
Health Awareness Boost
Urban India's wellness trend is here to stay. Online sales of supplements increased by 35% during FY24. Chemkart is well-positioned to ride this wave.
Product Innovation
New products in high-demand areas like plant proteins and immunity boosters can help increase profits and market share. However, competition from big FMCG players and raw material price pressure are still real issues to monitor.
Grey Market Premium (GMP)
The Grey Market Premium (GMP) is an unofficial indicator of how an IPO might perform on its listing day.
Latest SME IPO GMP
₹0 (as of July 3, 2025)
A zero-GMP reading means that the value range of the IPO is converging with what market players anticipate. This suggests the pricing is seen as fair, with neither a significant premium nor a discount expected at listing, based on current sentiment.
Conclusion: Do You Apply?
So, should you participate in the Chemkart India IPO? If you believe in India's health-and-wellness narrative and can stomach the SME segment's liquidity profile, a small allocation would be warranted.
At a price band of ₹236–₹248, you are betting on a growth story in its early innings, backed by a strong management team and a clear path to profitability.